• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pretreatment with P2Y12 inhibitors in non-ST-Segment-elevation acute coronary syndrome: an outdated and harmful strategy.

作者信息

Collet Jean-Philippe, Silvain Johanne, Bellemain-Appaix Anne, Montalescot Gilles

机构信息

From the Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtriėre (ACTION Study Group, AP-HP, Université Paris 6), Paris, France (J.-P.C., J.S., and G.M.); and Department of Cardiology, Hospital La Fontonne, Antibes, France (A.B.-A.).

出版信息

Circulation. 2014 Nov 18;130(21):1904-14; discussion 1914. doi: 10.1161/CIRCULATIONAHA.114.011320.

DOI:10.1161/CIRCULATIONAHA.114.011320
PMID:25403596
Abstract
摘要

相似文献

1
Pretreatment with P2Y12 inhibitors in non-ST-Segment-elevation acute coronary syndrome: an outdated and harmful strategy.非ST段抬高型急性冠状动脉综合征中P2Y12抑制剂的预处理：一种过时且有害的策略。
Circulation. 2014 Nov 18;130(21):1904-14; discussion 1914. doi: 10.1161/CIRCULATIONAHA.114.011320.
2
P2Y₁₂ receptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome.P2Y₁₂ 受体抑制剂：替格瑞洛在急性冠状动脉综合征治疗中的应用。
Ann Pharmacother. 2011 Sep;45(9):1151-6. doi: 10.1345/aph.1Q141. Epub 2011 Aug 18.
3
New antiplatelet agents in the treatment of acute coronary syndromes.新型抗血小板药物治疗急性冠脉综合征。
Arch Cardiovasc Dis. 2014 Mar;107(3):178-87. doi: 10.1016/j.acvd.2014.01.009. Epub 2014 Mar 11.
4
Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome is clinically justified.在非ST段抬高型急性冠状动脉综合征中，使用P2Y12抑制剂进行预处理在临床上是合理的。
Circulation. 2014 Nov 18;130(21):1891-903; discussion 1903. doi: 10.1161/CIRCULATIONAHA.114.011319.
5
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.替格瑞洛与氯吡格雷用于拟行直接经皮冠状动脉介入治疗的 ST 段抬高型急性冠状动脉综合征患者：血小板抑制和患者结局（PLATO）试验亚组分析。
Circulation. 2010 Nov 23;122(21):2131-41. doi: 10.1161/CIRCULATIONAHA.109.927582. Epub 2010 Nov 8.
6
Emerging oral antiplatelet therapies for acute coronary syndromes.急性冠状动脉综合征的新型口服抗血小板治疗方法。
Hosp Pract (1995). 2010 Nov;38(4):29-37. doi: 10.3810/hp.2010.11.337.
7
Ticagrelor for acute coronary syndromes.替格瑞洛用于急性冠状动脉综合征
Expert Rev Cardiovasc Ther. 2013 Nov;11(11):1473-84. doi: 10.1586/14779072.2013.839205. Epub 2013 Oct 23.
8
Pretreatment with P2Y12 inhibitors in non-ST-segment elevation acute coronary syndrome: Time to revise the guidelines?
Arch Cardiovasc Dis. 2014 Jan;107(1):1-3. doi: 10.1016/j.acvd.2013.10.004. Epub 2013 Dec 12.
9
Ticagrelor approved for acute coronary syndrome.替格瑞洛获批用于急性冠状动脉综合征。
Am J Health Syst Pharm. 2011 Sep 1;68(17):1568. doi: 10.2146/news110058.
10
Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).急性冠状动脉综合征行经皮冠状动脉介入治疗患者中当代口服抗血小板治疗指南的实施：来自希腊抗血小板登记研究（GRAPE）的报告。
Int J Cardiol. 2013 Oct 15;168(6):5329-35. doi: 10.1016/j.ijcard.2013.08.007. Epub 2013 Aug 15.

引用本文的文献

1
Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.坎格雷洛在急性冠状动脉综合征中的安全性和疗效：系统评价和网络荟萃分析。
Am J Cardiovasc Drugs. 2024 Jan;24(1):71-81. doi: 10.1007/s40256-023-00616-2. Epub 2023 Nov 23.
2
Chewed Versus Swallowed Ticagrelor in P2Y12 Inhibitor-Naïve Patients Undergoing Percutaneous Coronary Intervention.经皮冠状动脉介入治疗的P2Y12抑制剂初治患者中咀嚼与吞咽替格瑞洛的比较
J Patient Cent Res Rev. 2023 Apr 18;10(2):50-57. doi: 10.17294/2330-0698.2009. eCollection 2023 Spring.
3
Early Dual-Antiplatelet Therapy at the Emergency Department Is Associated with Lower In-Hospital Major Adverse Cardiac Event Risk among Patients with Non-ST-Elevation Myocardial Infarction.
急诊科早期双联抗血小板治疗与非ST段抬高型心肌梗死患者住院期间较低的主要不良心脏事件风险相关。
Cardiol Res Pract. 2021 Apr 22;2021:5571822. doi: 10.1155/2021/5571822. eCollection 2021.
4
Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial.非 ST 段抬高型急性冠脉综合征患者应用 P2Y12 受体拮抗剂的下游或上游给药：一项随机对照试验的研究方案。
Trials. 2020 Nov 24;21(1):966. doi: 10.1186/s13063-020-04859-1.
5
Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina.急性冠脉综合征和稳定性心绞痛患者中 P2Y12 抑制剂预负荷的获益和风险。
J Thromb Thrombolysis. 2017 Oct;44(3):303-315. doi: 10.1007/s11239-017-1529-6.
6
P2Y12 Inhibitor Pre-Treatment in Non-ST-Elevation Acute Coronary Syndrome: A Decision-Analytic Model.非ST段抬高型急性冠状动脉综合征中P2Y12抑制剂预处理：一种决策分析模型
J Clin Med. 2016 Aug 17;5(8):72. doi: 10.3390/jcm5080072.
7
When is the Best Time for the Second Antiplatelet Agent in Non-St Elevation Acute Coronary Syndrome?非ST段抬高型急性冠状动脉综合征中第二种抗血小板药物的最佳用药时间是什么时候？
Arq Bras Cardiol. 2016 Mar;106(3):236-46. doi: 10.5935/abc.20160042.
8
The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review.在首次住院期间更换P2Y12受体抑制剂治疗的影响：一项系统评价
Eur J Clin Pharmacol. 2016 Jan;72(1):83-91. doi: 10.1007/s00228-015-1949-1. Epub 2015 Oct 9.
9
Switching P2Y12-receptor inhibitors in patients with coronary artery disease.冠心病患者的 P2Y12 受体抑制剂转换。
Nat Rev Cardiol. 2016 Jan;13(1):11-27. doi: 10.1038/nrcardio.2015.113. Epub 2015 Aug 18.